Olema Pharmaceuticals Inc... (OLMA)
Olema Pharmaceuticals Statistics
Share Statistics
Olema Pharmaceuticals has 68.33M shares outstanding. The number of shares has increased by 22.17% in one year.
Shares Outstanding | 68.33M |
Shares Change (YoY) | 22.17% |
Shares Change (QoQ) | 19.26% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 54.63M |
Failed to Deliver (FTD) Shares | 17.59K |
FTD / Avg. Volume | 1.65% |
Short Selling Information
The latest short interest is 10.87M, so 15.91% of the outstanding shares have been sold short.
Short Interest | 10.87M |
Short % of Shares Out | 15.91% |
Short % of Float | 20.23% |
Short Ratio (days to cover) | 8.38 |
Valuation Ratios
The PE ratio is -2.65 and the forward PE ratio is -2.28. Olema Pharmaceuticals's PEG ratio is -0.94.
PE Ratio | -2.65 |
Forward PE | -2.28 |
PS Ratio | 0 |
Forward PS | 0.7 |
PB Ratio | 0.84 |
P/FCF Ratio | -3.28 |
PEG Ratio | -0.94 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Olema Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.5, with a Debt / Equity ratio of 0.
Current Ratio | 10.5 |
Quick Ratio | 10.5 |
Debt / Equity | 0 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.35M |
Employee Count | 96 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -68.13% in the last 52 weeks. The beta is 2.12, so Olema Pharmaceuticals's price volatility has been higher than the market average.
Beta | 2.12 |
52-Week Price Change | -68.13% |
50-Day Moving Average | 4.82 |
200-Day Moving Average | 9.36 |
Relative Strength Index (RSI) | 25.61 |
Average Volume (20 Days) | 1.06M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -142.26M |
Net Income | -129.47M |
EBITDA | -142.26M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.2 |
Balance Sheet
The company has 139.48M in cash and 1.43M in debt, giving a net cash position of 138.05M.
Cash & Cash Equivalents | 139.48M |
Total Debt | 1.43M |
Net Cash | 138.05M |
Retained Earnings | -435.11M |
Total Assets | 450.98M |
Working Capital | 396.71M |
Cash Flow
In the last 12 months, operating cash flow was -104.35M and capital expenditures 0, giving a free cash flow of -104.35M.
Operating Cash Flow | -104.35M |
Capital Expenditures | 0 |
Free Cash Flow | -104.35M |
FCF Per Share | -1.78 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
OLMA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for OLMA is $28, which is 735.8% higher than the current price. The consensus rating is "Buy".
Price Target | $28 |
Price Target Difference | 735.8% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | 1.92 |
Piotroski F-Score | 1 |